Degarelix

Mechanism

Unlike triptorelin (which stimulates before suppressing), degarelix immediately blocks the GnRH receptor, causing rapid testosterone suppression without any initial hormone spike. FDA-approved for prostate cancer. Relevant in the peptide community as an example of how GnRH antagonism works differently from agonism.

Effects

**Endocrine — Hypothalamic-Pituitary-Gonadal Axis (Tier 1 — Human Clinical):** Degarelix is a third-generation GnRH antagonist that competitively blocks GnRH receptors in the anterior pituitary, causing immediate and profound suppression of LH and FSH release. Unlike GnRH agonists, there is NO initial testosterone surge ("flare"). Testosterone reaches castrate levels (<50 ng/dL) within 3 days in 96% of patients, compared to 2–4 weeks with GnRH agonists. **Reproductive / Prostate (Tier 1 — Human Clinical):** Rapid PSA decline in advanced prostate cancer. Achieves faster and deeper PSA suppression than GnRH agonists in the first month, which may be clinically significant in patients with impending spinal cord compression or ureteral obstruction from prostate cancer. **Cardiovascular (Tier 1 — Human Clinical, Safety Concern):** All androgen deprivation therapy increases cardiovascular risk. However, pooled analysis of degarelix trials suggests potentially lower cardiovascular event rates compared to GnRH agonists, particularly in patients with pre-existing cardiovascular disease. The mechanism may relate to avoidance of the initial testosterone flare and FSH suppression (FSH receptors on vascular endothelium may promote atherosclerosis). **Musculoskeletal (Tier 1 — Human Clinical, Side Effect):** Like all androgen deprivation therapy, chronic degarelix use causes bone mineral density loss, increased fracture risk, sarcopenia, and metabolic syndrome. These are class effects of castrate testosterone levels, not specific to degarelix. **Hepatic (Tier 1 — Human Clinical):** Mild transaminase elevations reported in clinical trials. Generally not clinically significant. Liver function monitoring recommended.

Practitioner Guide

**APPROVED INDICATION:** • Advanced prostate cancer requiring androgen deprivation therapy (FDA-approved 2008, Firmagon). **DOSING:** • Loading dose: 240 mg subcutaneous (given as two 120 mg injections in the abdominal region) on Day 1. • Maintenance: 80 mg subcutaneous every 28 days. • Reconstitution: Requires careful technique — reconstitute with provided diluent, swirl gently (do NOT shake), allow to stand for dissolution. The solution must be clear before injection. **THE NO-FLARE ADVANTAGE (Deep Clinical Guidance):** • GnRH agonists (leuprolide, goserelin) initially cause a testosterone surge ("flare") lasting 2–3 weeks that can worsen symptoms: bone pain, urinary obstruction, spinal cord compression. Anti-androgen "cover" (bicalutamide) is typically co-prescribed to block the flare. • Degarelix eliminates this flare entirely — direct antagonism means immediate suppression without initial stimulation. This makes degarelix preferred in: - Patients with impending spinal cord compression from vertebral metastases - Patients with significant urinary obstruction - Patients with high-volume symptomatic metastatic disease - Patients who cannot tolerate anti-androgen cover • Clinical pearl: In practice, many oncologists/urologists still default to GnRH agonists + anti-androgen cover due to familiarity. The degarelix advantage is most impactful in symptomatic patients where flare could cause acute harm. **BONE DENSITY MONITORING DURING LONG-TERM USE:** • Baseline DEXA scan before or within 3 months of starting ADT. • Repeat DEXA every 1–2 years during treatment. • Start bone-protective therapy early: calcium 1200 mg/day + vitamin D 1000–2000 IU/day minimum. Consider denosumab or zoledronic acid if T-score < -1.0 or significant decline. • Weight-bearing exercise and resistance training are critical — prescribe structured exercise programs. **INJECTION SITE REACTIONS:** • Degarelix causes injection site reactions in ~40% of patients — pain, erythema, swelling, and induration at the SC injection site. This is significantly higher than GnRH agonists. • Clinical pearl: Use a 27G needle, inject deeply into subcutaneous tissue (not intradermally), and inject SLOWLY over 30 seconds. Warm the reconstituted solution to room temperature. Rotate injection sites. Despite reactions, only ~1% discontinue treatment due to injection site issues. **THE TRIPTORELIN PCT PHENOMENON (Off-Label Bodybuilding Context):** • Note: Degarelix is NOT used in the bodybuilding community — it produces sustained castration, which is the opposite of what PCT (post-cycle therapy) aims to achieve. • However, understanding GnRH antagonist pharmacology is relevant: a single dose of degarelix would cause weeks of testosterone suppression, making it wholly inappropriate for PCT. • The "triptorelin PCT" protocol (see leuprolide entry for related discussion) involves a SINGLE small dose of a GnRH agonist, not an antagonist. Antagonists like degarelix suppress immediately and persistently — they cannot "restart" the HPTA.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  Degarelix suppresses sex hormones and is expected to cause fetal harm. Contraindicated per Firmagon prescribing information.
  Action: Absolutely contraindicated during pregnancy.
• hard stop — Under 18 years of age
  GnRH antagonist. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Osteoporosis
  Androgen deprivation causes bone mineral density loss. Risk of pathologic fractures increases with duration of treatment.
  Action: Requires DEXA scan. Bone-protective co-therapy recommended. Monitor BMD.
• requires physician — Cardiovascular disease
  Androgen deprivation therapy is associated with increased cardiovascular risk. QT prolongation has been reported with degarelix.
  Action: Requires cardiovascular evaluation. Monitor ECG for QT prolongation. Monitor lipids and glucose.
• requires physician — QT prolongation or medications that prolong QT
  Degarelix may prolong the QT interval. Concurrent use with other QT-prolonging drugs increases risk of torsades de pointes and sudden cardiac death.
  Action: ECG monitoring required. Avoid concurrent QT-prolonging medications. Monitor electrolytes (potassium, magnesium).
• monitor — Hepatic impairment
  Degarelix undergoes hepatic metabolism. Mild-to-moderate hepatic impairment may alter drug clearance.
  Action: Monitor liver function. No formal dose adjustment established.

Evidence

• Risk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis.

  Odat et al. (2025) — Urol Oncol — PMID: 39818461

  Recent meta-analysis suggests degarelix may have a cardiovascular safety advantage versus GnRH agonists in prostate cancer, which is clinically relevant when selecting androgen-deprivation regimens for higher-risk patients.

  strong

• The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (CS21)

  Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH (2008) — BJU International — PMID: 19154461

  Degarelix (GnRH antagonist) achieved faster testosterone suppression than leuprolide (96% at day 3 vs 0% for leuprolide) without testosterone flare in the CS21 Phase 3 trial. Both treatments maintained castrate levels at 12 months. Degarelix showed significantly lower PSA failure rates and no testosterone microsurges. Eliminates need for anti-androgen flare protection required with GnRH agonists.

  strong

Research Summary

**Tier 1 (Human Clinical Evidence):** • CS21 pivotal trial: Degarelix 240/80 mg was non-inferior to leuprolide 7.5 mg monthly for testosterone suppression at 1 year, but achieved castrate levels significantly faster (96% by Day 3 vs ~0% for leuprolide). Published in Journal of Urology. • PSA progression-free survival: Degarelix showed superior PSA-PFS in patients with high baseline PSA (>20 ng/mL) in post-hoc analysis, suggesting benefit in high-risk disease. • Cardiovascular pooled analysis: Significantly fewer cardiovascular events with degarelix vs GnRH agonists in patients with pre-existing cardiovascular disease (retrospective pooled analysis of 6 trials). • Injection site reactions: Well-documented (40% incidence) but rarely treatment-limiting. **Tier 2 (Strong Preclinical + Mechanistic):** • FSH suppression hypothesis: Degarelix suppresses both LH and FSH, while GnRH agonist-treated patients may have incomplete FSH suppression. Since FSH receptors on vascular endothelium may promote atherosclerosis, this could explain the cardiovascular advantage. Mechanism is under active investigation. • Direct pituitary antagonism is pharmacologically clean — no paradoxical activation phase. **Tier 3 (Emerging / Theoretical):** • Ongoing trials comparing degarelix (and next-generation oral GnRH antagonists like relugolix) to GnRH agonists in the cardiovascular context. • Potential role in breast cancer (GnRH receptor-expressing tumors) is early-stage.